natgillin/translations-raw huggingface dataset:
Desuden tyder begrænsede kliniske data på, at tilføjelse af delamanid til behandlingsplaner for behandling af MDR-TB, der er resistent over for rifampicin og isoniazid, men ellers disponeret, gav den største virkning, mens brug af delamanid som en del af den bedste tilgængelige behandlingsplan, der kunne opstilles for behandling af XDR-TB, blev sat i forbindelse med den laveste virkning.
In addition, limited clinical data indicate that the addition of delamanid to regimens for treating MDR-TB that were resistant to rifampicin and isoniazid but otherwise susceptible, gave the highest efficacy whereas use of delamanid as part of the best available regimens that could be constructed for treating XDR-TB was associated with the lowest efficacy.
Desuden udførte ansøgeren en bioækvivalensundersøgelse hos 58 patienter over 6 år med cystisk fibrose for at fastslå, om Vantobra frembringer samme mængde af det aktive stof i kroppen som referencelægemidlet Tobi.
In addition, the applicant conducted a ‘bioequivalence’ study in 58 patients with cystic fibrosis aged 6 years and above to determine whether Vantobra produces similar levels of the active substance in the body as the reference medicine, Tobi.
Desuden udviste Revestive en acceptabel sikkerhedsprofil ved behandling af op til et års varighed hos voksne.
Furthermore, Revestive showed an acceptable safety profile for up to one year of treatment in adults.
Desuden understregede udvalget, at der er behov for nye midler til behandling af multiresistent tuberkulose.
Furthermore the Committee highlighted the medical need for new agents to treat multi-drug resistant tuberculosis.
Desuden var begge doseringsregimer effektive til at nedsætte viral belastningen.
Also, both dosing regimens were effective in reducing the viral load.
Desuden var behandling med panitumumab forbundet med bedre PFS sammenlignet med BSC hos patienter med vildtype-RAS-tumorer (HR = 0,38 [95 % CI: 0,27; 0,56]), men ikke hos patienter med tumorer, der skjulte en RAS-mutation (HR = 0,98 [95 % CI: 0,73; 1,31]).
Moreover, panitumumab treatment was associated with improved PFS compared to BSC in patients with wild-type RAS tumours (HR = 0.38 [95% CI: 0.27, 0.56]), but not in patients with tumours harbouring a RAS mutation (HR = 0.98 [95% CI: 0.73, 1.31]).
Desuden var de hyppigste bivirkninger hos børn med ITP også forkølelse, nasopharyngitis (betændelse i næse og hals), rhinitis (betændelse i næseslimhinden), smerter i mave eller i mund og hals, tandpine, udslæt, løbende næse og abnormt indhold af visse leverenzymer i blodet (AST).
In addition, in children with ITP the most common side effects also included colds, nasopharyngitis (inflammation of the nose and throat), rhinitis (inflammation of the lining of the nose), pain in the tummy or in the mouth and throat, toothache, rash, runny nose and abnormal blood levels of certain liver enzymes (AST).
Desuden var de observerede trough nevirapin koncentrationer sammenlignelige med de to metoder til beregning af dosis.
In addition, the observed trough nevirapine concentrations were comparable between the two methods.
Desuden var der flere af de patienter, der fik Empliciti-kombinationsbehandlingen, som oplevede, at kræften forsvandt helt eller delvist (79 %), end af de patienter, der fik de to andre lægemidler alene (66 %).
In addition, more patients had a partial or complete clearing of their cancer with the Empliciti combination (79% of patients) than with only the other two medicines (66% of patients).
Desuden var der fortsat beskyttende immunitet mod hepatitis B efter primær vaccination med 2 doser og en boosterdosis hos ≥ 48 % af personerne i alderen 11-12 år.
Additionally, following a 2-dose primary and booster schedule, protective immunity against hepatitis B persisted in ≥ 48% of subjects 11-12 years of age.
Desuden var der færre bivirkninger hos patienter behandlet med MACI end hos patienter behandlet med mikrofrakturoperation.
In addition, patients treated with MACI had fewer side effects compared with microfracture- treated patients.
Desuden var der ingen væsentlige sikkerhedsproblemer forbundet med Enurev Breezhaler, hvis bivirkninger svarer til dem, der er forbundet med andre antikolinerge bronkodilatorer.
In addition, there were no major safety concerns with Enurev Breezhaler, with side effects being similar to other anticholinergic bronchodilator medicines.
Desuden var der ingen væsentlige sikkerhedsproblemer forbundet med Seebri Breezhaler, hvis bivirkninger svarer til dem, der er forbundet med andre antikolinerge bronkodilatorer.
In addition, there were no major safety concerns with Seebri Breezhaler, with side effects being similar to other anticholinergic bronchodilator medicines.
Desuden var der ingen væsentlige sikkerhedsproblemer forbundet med Tovanor Breezhaler, hvis bivirkninger svarer til dem, der er forbundet med andre antikolinerge bronkodilatorer.
In addition, there were no major safety concerns with Tovanor Breezhaler, with side effects being similar to other anticholinergic bronchodilator medicines.
Desuden var der seks tilfælde med symptomer, der kunne tyde på LSCD, for eksempel 'konjunktivalisering' (invasion af conjunctivaceller i cornea) samt defekter i corneal epithelium.
Furthermore, 6 cases presented with symptoms indicative for LSCD, such as conjunctivalisation (invasion of conjunctival cells in the cornea) and corneal epithelial defects.
Desuden var der støttende dokumentation, der viste fordel af at kombinere lægemidlet med insulin.
There was also supportive evidence suggesting benefit when the medicine was combined with insulin.
Desuden var feber mere udbredt hos børn i alderen 6- 9 år end hos børn i alderen 3-5 år.
Also fever occurred more often in children aged 6-9 years compared to the children aged 3-5 years.
Desuden var forekomsten af symptomatisk VTE (symptomatisk DVT, ikke-letal PE og VTE-relateret dødsfald) i alle tre studier lavere hos patienter, der blev behandlet med rivaroxaban, end hos patienter, der blev behandlet med enoxaparin.
Furthermore, in all three studies the rate of symptomatic VTE (symptomatic DVT, non- fatal PE, VTE-related death) was lower in rivaroxaban treated patients compared to patients treated with enoxaparin.
Desuden var GMC-værdierne lavere, hvad angår antistoffer, for de fleste serotyper efter en spædbørnsvaccination bestående af to doser end efter en spædbørnsvaccination bestående af tre doser.
In addition, GMCs were lower for antibodies to most serotypes after a two- dose infant series than after a three-dose infant series.
Desuden var Instanyl signifikant bedre end placebo til lindring af gennembrudssmerter ved 10, 20, 40 og 60 minutter efter administration.
Furthermore Instanyl was significantly superior to placebo in BTP relief at 10, 20, 40, and 60 minutes following administration.
Desuden var IPA på 32 % (24 timer) og 61 % (dag 5), hvilket var større end hos personer med poor metabolisme, der fik 300 mg/75 mg-regimet, og svarede til IPA ved 300 mg/75 mg regimet hos de andre grupper af CYP2C19- metabolisers.
In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen.
Desuden var IPA på 32 % (24 timer) og 61 % (dag 5), hvilket var større end hos poor metabolisers, der fik 300 mg/75 mg-regimet, og svarede til IPA ved 300 mg/75 mg regimet hos de andre grupper af CYP2C19- metabolisers.
In addition, IPA was 32% (24 hours) and 61% (Day 5), which were greater than in the poor metabolisers receiving the 300 mg/75 mg regimen, and were similar to the other CYP2C19 metaboliser groups receiving the 300 mg/75 mg regimen.
Desuden var patienternes rapporterede søvnkvalitet, antal opvågninger og årvågenhed om morgenen signifikant forbedre i Circadin-gruppen sammenlignet med placebo- gruppen.
In addition, patients’ self-reported quality of sleep, number of awakenings and morning alertness significantly improved with Circadin compared to placebo.
Desuden var region (Europa/Australien vs.
Additionally, region (Europe/Australia vs.
Desuden var risikoen for nye rygsøjlebrud efter tre år lavere hos patienter, der fik Prolia.
In addition, after three years the risk of new spine fractures was lower in patients who received Prolia.
Desuden var størrelsesordenen af forbedringer i ppFEV1 ved dag 15 af behandling med lumacaftor/ivacaftor (lumacaftor 400 mg/ivacaftor 250 mg hver 12. time) i studie 3 (figur 1) for patienter i behandling med placebo i 24 uger i studie 1 eller studie 2 3,0 procentpoint absolut og 4,8 % relativ ændring fra studie 3 baseline, hvilket svarede til forbedringerne observeret i de aktive behandlingsgrupper i studie 1 og studie 2.
In addition, for patients treated with placebo for 24 weeks in Trial 1 or Trial 2, the magnitude of improvement in ppFEV1 at Day 15 of lumacaftor/ivacaftor (lumacaftor 400 mg/ivacaftor 250 mg q12h) treatment in Trial 3 (Figure 1), 3.0 percentage points absolute and 4.8% relative change from Trial 3 baseline, was similar to the improvement observed in the active treatment groups in Trial 1 and Trial 2.
Desuden ved vi ikke, hvordan Revlimid påvirker din risiko for at få AML.
In addition, we do not know how Revlimid affects the chances of you getting AML.
Desuden vil den virksomhed, der fremstiller Nulojix, vedlægge hver lægemiddelpakning et advarselskort med oplysninger om fordelene og risiciene ved Nulojix.
In addition, the company that makes Nulojix will include an alert card in each medicine’s pack to increase awareness of the benefits and risks with Nulojix.
Desuden vil den virksomhed, der markedsfører Soliris, sørge for, at lægemidlet først udleveres, når det er fastslået, at patienten er blevet korrekt vaccineret.
In addition, the company that markets Soliris will ensure that distribution of the medicine occurs only after checking that the patient has been vaccinated appropriately.
Desuden vil det blive kontrolleret, om Deres lever og nyrer fungerer rigtigt. ,
In addition, the proper function of your liver and your kidneys will be checked.
Desuden vil studiet optage og følge patienter med negativ status for RET-mutation, som ikke får vandetanib på grund af RET-status eller kontraindikation.
In addition, RET mutation negative patients who do not receive vandetanib due to RET status or contraindication will be allowed to enrol and followed.
Desuden vil virksomheden foretage en undersøgelse af patienter med myelodysplastiske syndromer for at indsamle yderligere sikkerhedsoplysninger og en sikkerhedsundersøgelse hos patienter med nydiagnosticeret multipelt myeloma, der ikke egner sig til en transplantation.
In addition, the company will carry out a study in patients with myelodysplastic syndromes to gather further safety data, as well as a safety study in patients with newly diagnosed multiple myeloma not eligible for transplant.
Desuden viser undersøgelserne, at defibrotid kan beskytte de celler, der beklæder blodkarrene indvendigt.
In addition, there is experimental evidence that Defibrotide may protect the cells lining blood vessels.
Desuden viste et interaktionsforsøg med omeprazol (CYP2C19-hæmmer) ingen klinisk relevante ændringer i plasmakoncentrationerne af lacosamid, hvilket kunne tyde på, at denne eliminationsvej har mindre betydning.
Furthermore an interaction trial with omeprazole (CYP2C19-inhibitor) demonstrated no clinically relevant changes in lacosamide plasma concentrations indicating that the importance of this pathway is minor.
Desuden viste post hoc analyser fra kliniske studier, at Velphoro ikke har nogen indvirkning på den iPTH-sænkende effekt af orale vitamin D- analoger.
In addition, post-hoc analyses from clinical studies demonstrated no impact of Velphoro on iPTH lowering effect of oral Vitamin D analogues.
Desuden vurderedes "no significant nausea" i hele perioden (0-120 timer efter kemoterapi) som et eksplorativt endepunkt, og i de akutte og forsinkede faser som en post-hoc analyse.
120 hours post-chemotherapy) was evaluated as an exploratory endpoint, and in the acute and delayed phases as a post-hoc analysis.
Desuden, blev en patient fra pre-autorisationsfasen indlagt på grund af hypertensiv krise.
In addition, 1 patient from the pre-authorisation phase was hospitalized due to hypertensive crisis.
Desuden, kan korrekt dosisjustering ikke opnås med kapselformuleringen hos patienter med en kropsoverflade på mindre end 1.33 m2.
Moreover, in patients with a body surface area of less than 1.33 m² appropriate dose adjustments cannot be achieved with the capsule formulation.
Det
It is
Det
risk.
Det 3-dages oral aprepitant-regime medførte en reduktion på omkring 30-35% af CYP2C9- substraternes AUC og et fald på op til 64% i ethinylestradiols dalkoncentration.
The 3-day oral aprepitant regimen resulted in an about 30-35 % reduction in AUC of CYP2C9 substrates and up to a 64 % decrease in ethinyl estradiol trough concentrations.
Det 3-årige hovedforsøg blev forlænget to gange med to 2-års dobbeltblind, placebo-kontrollerede forlængelser, hvilket gav en samlet behandlingevarighed på op til 7 år (7-årigtforsøg).
The 3-year core study was extended twice, with two 2-year double-blind, placebo- controlled extensions, resulting in a total treatment duration of up to 7 years (7-year study).
Det administreres normalt sammen med heparin eller lavmolekylært heparin.
It is normally given in association with heparin or low molecular weight heparin.
Det adskiller sig fra endogent humant KGF ved, at de første 23 N-terminale aminosyrer er fjernet for at forbedre proteinstabiliteten.
It differs from endogenous human KGF in that the first 23 N-terminal amino acids have been deleted to improve protein stability.
Det afbryder ikke en graviditet, hvis du allerede er gravid.
If you are already pregnant, it will not interrupt an existing pregnancy.
Det afhænger af din sygdom, hvor mange Icandratabletter du skal tage.
The amount of Icandra that people have to take varies depending on their condition.
Det afslapper den glatte muskulatur i karrene ved at binde sig til hæm-delen af cytosolguanylatcyclase, idet det aktiverer guanylatcyclase og forøger de intracellulære koncentrationer af cyklisk guanosin 3’,5’-monophosphat, som så medfører vasodilatation.
It relaxes vascular smooth muscle by binding to the haeme moiety of cytosolic guanylate cyclase, activating guanylate cyclase and increasing intracellular levels of cyclic guanosine 3’,5’-monophosphate, which then leads to vasodilation.
Det aktive indholdsstof er ibandronsyre
It contains the active substance ibandronic acid.
Det aktive indholdsstof er obinutuzumab: 1000 mg/40 ml per hætteglas svarende til en koncentration på 25 mg/ml inden fortynding.
The active substance is obinutuzumab: 1,000 mg/40 mL per vial corresponding to a concentration before dilution of 25 mg/mL.
Det Aktive indholdsstof er vismodegib.
The active substance is vismodegib.
Det aktive indholdsstof hydrochlorthiazid kan være årsag til en usædvanlig reaktion, hvilket kan resultere i synsnedsættelse og øjensmerter.
The active ingredient hydrochlorothiazide can cause an unusual reaction, resulting in a decrease in vision and eye pain.
Det aktive indholdsstof i Caelyx er doxorubicin hydrochlorid, et cytotoksisk antracyklin-antibiotikum, der er udvundet af Streptomyces peucetius var. caesius.
The active ingredient of Caelyx is doxorubicin hydrochloride, a cytotoxic anthracycline antibiotic obtained from Streptomyces peucetius var. caesius.
Det aktive indholdsstof i hydrochloridthiazide kan forårsage en usædvanlig reaktion, hvilket medfører nedsat syn og øjensmerter.
The active ingredient hydrochlorothiazide can cause an unusual reaction, resulting in a decrease in vision and eye pain.
Det aktive indholdsstof i RILUTEK er riluzol, som virker på nervesystemet.
The active substance in RILUTEK is riluzole which acts on the nervous system.
Det aktive indholdsstof i Viracept er nelfinavir.
The active substance in Viracept is nelfinavir.
Det aktive indholdsstof i Vistide, cidofovir, er et antiviralt lægemiddel, som tilhører gruppen af 'nukleosidanaloger’.
The active substance in Vistide, cidofovir, is an antiviral medicine that belongs to the class ‘nucleotide analogues’.
Det aktive indholdsstof tilmanocept bindes specifikt til mannosebindende recep- torproteiner (CD206) på overfladen af makrofager og dendritceller.
The drug substance, tilmanocept, specifically binds to mannose binding receptor proteins (CD206) that reside on the surface of macrophages and dendritic cells.
Det aktive indholdsstof, pregabalin, er en gamma-aminosmørsyre analog [(S)-3-(aminomethyl)-5-methylhexansyre].
The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-3- (aminomethyl)-5- methylhexanoic acid].
Det aktive indholdsstof, pregabalin, er en gamma-aminosmørsyre analog [(S)-3-(aminomethyl)-5-methylhexansyre].
The active substance, pregabalin, is a gamma-aminobutyric acid analogue [(S)-3-(aminomethyl)- 5- methylhexanoic acid].
Det aktive indholdsstof, pregabalin, er en gamma-aminosmørsyre-analog [(S)-3- (aminomethyl)-5- methylhexansyre].
The active substance, pregabalin, is a gamma-aminobutyric acid analogue ((S)-3-(aminomethyl)-5- methylhexanoic acid).
Det aktive lægemiddelstof i Lamivudin Teva er lamivudin.
The active ingredient in Lamivudine Teva is lamivudine.
Det aktive stof (duloxetin) i ARICLAIM bruges i andre lægemidler mod andre tilstande: depression, angst og stressinkontinens
The main ingredient of ARICLAIM, duloxetine, is used in other medicines for other conditions: depression, anxiety and urinary incontinence
Det aktive stof (duloxetin) i Cymbalta bruges i andre lægemidler mod andre tilstande: diabetisk neuropatisk smerte, depression, angst og stressinkontinens.
The main ingredient of Cymbalta, duloxetine, is used in other medicines for other conditions: diabetic neuropathic pain, depression, anxiety and urinary incontinence
Det aktive stof (duloxetin) i DULOXETIN BOEHRINGER INGELHEIM bruges i andre lægemidler mod andre tilstande: depression, angst og stressinkontinens
The main ingredient of DULOXETINE BOEHRINGER INGELHEIM, duloxetine, is used in other medicines for other conditions: depression, anxiety and urinary incontinence.
Det aktive stof (duloxetin) i Duloxetin Lilly bruges i andre lægemidler mod andre tilstande: diabetisk neuropatisk smerte, depression, angst og stressinkontinens.
The main ingredient of Duloxetine Lilly, duloxetine, is used in other medicines for other conditions: diabetic neuropathic pain, depression, anxiety and urinary incontinence
Det aktive stof (duloxetin) i Xeristar bruges i andre lægemidler mod andre tilstande: diabetisk neuropatisk smerte, depression, angst og stressinkontinens
The main ingredient of Xeristar, duloxetine, is used in other medicines for other conditions: diabetic neuropathic pain, depression, anxiety and urinary incontinence
Det aktive stof (duloxetin) i YENTREVE bruges i andre lægemidler mod andre tilstande: diabetisk neuropatisk smerte, depression, angst og stressinkontinens
The main ingredient of YENTREVE, duloxetine, is used in other medicines for other conditions: diabetic neuropathic pain, depression, anxiety and urinary incontinence
Det aktive stof ChondroCelect består af en behandlingsdosis af levedygtige autologe humane bruskceller i hætteglas indeholdende 4 millioner celler i 0,4 ml svarende til en koncentration på 10.000 celler/mikroliter.
The active substance of ChondroCelect consists of a treatment dose of viable autologous human cartilage cells in vials containing 4 million cells in 0.4 ml, corresponding to a concentration of 10,000 cells/microlitre.
Det aktive stof edoxabantosilat er persisterende i miljøet (for anvisninger i bortskaffelse, se pkt.
The active substance edoxaban tosilate is persistent in the environment (for instructions on disposal see section 6.6).
Det aktive stof er (90Y) Yttriumchlorid.
The active substance is Yttrium (90Y) chloride.
Det aktive stof er 1,5 mg fondaparinuxnatrium i 0,3 ml injektionsvæske
The active substance is 1.5 mg fondaparinux sodium in 0.3 ml solution for injection
Det aktive stof er 2,5 mg fondaparinuxnatrium i 0,5 ml injektionsvæske
The active substance is 2.5 mg fondaparinux sodium in 0.5 ml solution for injection
Det aktive stof er 30 mg jern som ferrimaltol.
The active substance is 30 mg of iron as ferric maltol.
Det aktive stof er agalsidase alfa (1 mg/ml).
The active substance in Replagal is agalsidase alfa (1mg/ml).
Det aktive stof er Aripiprazole.
The active substance is aripiprazole.
Det aktive stof er avanafil.
The active substance is avanafil.
Det aktive stof er betain, vandfrit.
The active substance is betaine anhydrous.
Det aktive stof er capecitabin
The active substance is capecitabine.
Det aktive stof er capecitabin.
The active substance is capecitabine.
Det aktive stof er cholsyre.
The active substance is cholic acid.
Det aktive stof er cysteamin (som mercaptaminbitartrat).
The active substance is cysteamine (as mercaptamine bitartrate).
Det aktive stof er cysteaminbitartrat (mercaptaminbitartrat).
The active substance is cysteamine bitartrate (mercaptamine bitartrate).
Det aktive stof er daclizumab
The active substance is daclizumab.
Det aktive stof er defibrotid.
The active substance is defibrotide.
Det aktive stof er dexamethason.
The active substance is dexamethasone.
Det aktive stof er dulaglutid.
The active substance is dulaglutide.
Det aktive stof er efalizumab, hvert hætteglas indeholder en optrækningsmængde på 125 mg efalizumab.
The active substance is efalizumab, each vial contains a deliverable dose of 125 mg efalizumab.
Det aktive stof er epoetin beta.
The active substance is epoetin beta.
Det aktive stof er et hvidt pulver, som ligger i en blisterstrip inde i inhalatoren.
The active substance is present as a white powder in a blister strip inside the inhaler.
Det aktive stof er fampridin.
The active substance is fampridine.
Det aktive stof er human protein C
The active substance is human protein C
Det aktive stof er ibandronsyre
The active substance is ibandronic acid.
Det aktive stof er ibandronsyre.
The active substance is ibandronic acid.
Det aktive stof er imiquimod.
The active substance is imiquimod.
Det aktive stof er insulin lispro.
The active substance is insulin lispro.
Det aktive stof er ioflupan (123I).
The active substance is ioflupane (123I).
Det aktive stof er kobber (64Cu)-chlorid.
The active substance is copper (64Cu) chloride.
Det aktive stof er leflunomid.
The active substance is leflunomide.
Det aktive stof er memantinhydrochlorid.
The active substance is memantine hydrochloride.
Det aktive stof er nateglinid.
The active substance is nateglinide.
Det aktive stof er olanzapin
The active substance is olanzapine
Det aktive stof er olanzapin.
The active substance is olanzapine.
Det aktive stof er oseltamivir (12 mg/ml oseltamivir efter rekonstituering)
The active substance is oseltamivir (12 mg/ml oseltamivir after reconstitution).
Det aktive stof er oseltamivir (6 mg/ml oseltamivir efter rekonstituering)
The active substance is oseltamivir (6 mg/ml oseltamivir after reconstitution).
Det aktive stof er palivizumab.
The active substance is palivizumab.
Det aktive stof er pancreas-pulver udvundet af pancreas (bugspytkirtler) fra svin.
The active substance is pancreas powder of porcine origin.
Det aktive stof er pegloticase.
The active substance is pegloticase.
Det aktive stof er permetexed.
The active substance is pemetrexed.
Det aktive stof er pioglitazon.
The active substance is pioglitazone.
Det aktive stof er propranolol.
The active substance is propranolol.
Det aktive stof er raloxifenhydrochlorid.
The active substance is raloxifene hydrochloride.
Det aktive stof er raltegravir.
The active substance is raltegravir.
Det aktive stof er ramucirumab.
The active substance is ramucirumab.
Det aktive stof er ribavirin 200 mg.
The active substance is ribavirin 200 mg.
Det aktive stof er roflumilast.
The active substance is roflumilast.
Det aktive stof er somatropin.
The active substance is somatropin.
Det aktive stof er stiripentol.
The active substance is stiripentol.
Det aktive stof er sunitinib.
The active substance is sunitinib.